The effect of SR 141716 and apomorphine on sensorimotor gating in Swiss mice

Pharmacology Biochemistry and Behavior

Volumn 77, Issue 4, 2004, Pages 839-845

  Malone, Daniel T ^a   Long, Leonora E ^a   Taylor, David A ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Apomorphine; Prepulse inhibition; Sensorimotor gating; SR 141716; Startle response

Indexed keywords

APOMORPHINE; CANNABINOID RECEPTOR ANTAGONIST; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; RIMONABANT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; AUDITORY STIMULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; MALE; MOUSE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; SENSORIMOTOR FUNCTION; STARTLE REFLEX;

ANIMALS; APOMORPHINE; DRUG COMBINATIONS; MALE; MICE; PIPERIDINES; PSYCHOMOTOR PERFORMANCE; PYRAZOLES; STARTLE REACTION;

EID: 1942455357     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2004.02.010     Document Type: Article

References (48)

1. 2 function. Neuroscience. 91:1999;607-620.
2. Bass C.E., Griffin G., Grier M., Mahadevan A., Razdan R.K., Martin B.R. SR-141716A-induced stimulation of locomotor activity: a structure-activity relationship study. Pharmacol. Biochem. Behav. 74:2002;31-40.
3. Bolino F., Di Michele V., Di Cicco L., Manna V., Daneluzzo E., Casacchia M. Sensorimotor gating and habituation evoked by electro-cutaneous stimulation in schizophrenia. Biol. Psychiatry. 36:1994;670-679.
4. Braff D.L., Grillon C., Geyer M.A. Gating and habituation of the startle reflex in schizophrenic patients. Arch. Gen. Psychiatry. 49:1992;206-215.
5. Cadenhead K.S., Geyer M.A., Braff D.L. Impaired startle prepulse inhibition and habituation in patients with schizotypal personality disorder. Am. J. Psychiatry. 150:1993;1862-1867.
6. Castellanos F.X., Fine E.J., Kaysen D., Marsh W.L., Rapoport J.L., Hallett M. Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Biol. Psychiatry. 39:1996;33-41.
7. Chaperon F., Thiebot M.H. Behavioral effects of cannabinoid agents in animals. Crit. Rev. Neurobiol. 13:1999;243-281.
8. Compton D.R., Aceto M.D., Lowe J., Martin B.R. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 277:1996;586-594.
9. Curzon P., Decker M.W. Effects of phencyclidine (PCP) and (+)MK-801 on sensorimotor gating in CD-1 mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 22:1998;129-146.
10. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
11. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G.et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. [see comments] Science. 258:1992;1946-1949.
12. Dulawa S.C., Geyer M.A. Psychopharmacology of prepulse inhibition in mice. Chin. J. Physiol. 39:1996;139-146.
13. Emrich H.M., Leweke F.M., Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol. Biochem. Behav. 56:1997;803-807.
14. Faraday M.M., Grunberg N.E. The importance of acclimation in acoustic startle amplitude and pre-pulse inhibition testing of male and female rats. Pharmacol. Biochem. Behav. 66:2000;375-381.
15. Felder C.C., Nielsen A., Briley E.M., Palkovits M., Priller J., Axelrod J.et al. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett. 393:1996;231-235.
16. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology. 156:2001;117-154.
17. Gray J.A. Dopamine release in the nucleus accumbens: the perspective from aberrations of consciousness in schizophrenia. Neuropsychologia. 33:1995;1143-1153.
18. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R.et al. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U. S. A. 87:1990;1932-1936.
19. Hoffman H.S., Ison J.R. Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input. Psychol. Rev. 87:1980;175-189.
20. Ison J.R., Hoffman H.S. Reflex modification in the domain of startle: II. The anomalous history of a robust and ubiquitous phenomenon. Psychol. Bull. 94:1983;3-17.
21. Jarbe T.U.C., Andrzejewski M.E., DiPatrizio N.V. Interactions between the CB1 receptor agonist delta(9)-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacol. Biochem. Behav. 73:2002;911-919.
22. Landsman R.S., Burkey T.H., Consroe P., Roeske W.R., Yamamura H.I. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol. 334:1997;R1-R2.
23. Leweke F.M., Giuffrida A., Wurster U., Emrich H.M., Piomelli D. Elevated endogenous cannabinoids in schizophrenia. NeuroReport. 10:1999;1665-1669.
24. MacLennan S., Reynen P.H., Kwan K., Bonhaus D.W. Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br. J. Pharmacol. 124:1998;619-622.
25. 9- tetrahydrocannabinol-induced hypothermia by fluoxetine in the rat. Br. J. Pharmacol. 124:1998;1419-1424.
26. Mansbach R.S., Rovetti C.C., Winston E.N., Lowe J.A. Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology (Berl.). 124:1996;315-322.
27. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G.et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 418:2002 (Aug 1);488-489.
28. Martellotta M.C., Cossu G., Fattore L., Gessa G.L., Fratta W. Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience. 85:1998;327-330.
29. Martin R., Secchi R., Sung E., Lemaire M., Bonhaus D., Hedley L.et al. Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat. Psychopharmacology (Berl.). 165:2003;128-135.
30. Mato S., Pazos A., Valdizan E.M. Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain. Eur. J. Pharmacol. 443:2002;43-46.
31. Mazzola C., Micale V., Drago F. Amnesia induced by [beta]-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur. J. Pharmacol. 477:2003;219-225.
32. Meschler J., Kraichely D.M., Wilken G.H., Howlett A.C. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4- methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano- 5-(4-methoxyphenyl)-1H-pyrazole-3-carboxylic acid phenylamide (CP-272871) for the CB1 cannabinoid receptor. Biochem. Pharmacol. 60:2000;1315-1323.
33. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
34. Poncelet M., Barnouin M.C., Breliere J.C., Le Fur G., Soubrie P. Blockade of cannabinoid (CB1) receptors by SR 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacologia. 144:1999;144-150.
35. 2 receptor agonists disrupt prepulse inhibition of startle in mice. Neuropsychopharmacology. 28:2003;108-118.
36. Ravinet Trillou C., Arnone M., Delgorge C., Gonalons N., Keane P., Maffrand J.-P.et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol., Regul. Integr. Comp. Physiol. 284:2003;R345-R353.
37. Richardson J.D., Aanonsen L., Hargreaves K.M. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur. J. Pharmacol. 319:1997;R3-R4.
38. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C.et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
39. Santucci V., Storme J.-J., Soubrie P., Le Fur G. Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-walking cycle analysis. Life Sci. 58:1996;PL103-PL110.
40. Schneider M., Koch M. The cannabinoid agonist WIN 55,212-2 reduces sensorimotor gating and recognition memory in rats. Behav. Pharmacol. 13(1):2002;29-37.
41. Sim-Selley L., Brunk L., Selley D. Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur. J. Pharmacol. 414:2001;135-143.
42. Souilhac J., Poncelet M., Rinaldi-Carmona M., LeFur G., Soubrie P. Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice. Pharmacol. Biochem. Behav. 51:1995;3-7.
43. Swerdlow N.R. Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav. Pharmacol. 11:2000;185-204.
44. Swerdlow N.R., Benbow C.H., Zisook S., Geyer M.A., Braff D.L. A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder. Biol. Psychiatry. 33:1993;298-301.
45. Swerdlow N.R., Paulsen J., Braff D.L., Butters N., Geyer M.A., Swenson M.R. Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J. Neurol. Neurosurg. Psychiatry. 58:1995;192-200.
46. Swerdlow N.R., Taaid N., Halim N., Randolph E., Kim Y.K., Auerbach P. Hippocampal lesions enhance startle gating-disruptive effects of apomorphine in rats: a parametric assessment. Neuroscience. 96:2000;523-536.
47. Terranova J.P., Storme J.J., Lafon N., Perio A., Rinaldi-Carmona M., Le Fur G.et al. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology. 126:1996;165-172.
48. Varty G.B., Walters N., Cohen-Williams M., Carey G.J. Comparison of apomorphine, amphetamine and dizocilpine disruptions of prepulse inhibition in inbred and outbred mice strains. Eur. J. Pharmacol. 424:2001;27-36.